SEC Comment Letter for ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510) (VISK) — Dec 18, 2009
ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)
Date: Dec. 18, 2009 · CIK: 0000727510 · Accession: 0000000000-09-071476
AI Filing Summary & Sentiment
Reasoning
Letter
Via Facsimile and U.S. Mail Mail Stop 4720 December 17, 2009 Mr. Craig A. Tooman EVP, Finance & Chief Financial Officer Enzon Pharmaceuticals, Inc. 685 Route 202/206 Bridgewater, NJ 08807
Re: Enzon Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2008 DEF 14A filed April 13, 2009 File No. 0-12957
Dear Mr. Tooman: We have completed our review of your Fo rm 10-K and related filings and have no further comments at this time. S i n c e r e l y , G u s R o d r i g u e z A c c o u n t i n g B r a n c h C h i e f
Show Raw Text
Via Facsimile and U.S. Mail Mail Stop 4720 December 17, 2009 Mr. Craig A. Tooman EVP, Finance & Chief Financial Officer Enzon Pharmaceuticals, Inc. 685 Route 202/206 Bridgewater, NJ 08807 Re: Enzon Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2008 DEF 14A filed April 13, 2009 File No. 0-12957 Dear Mr. Tooman: We have completed our review of your Fo rm 10-K and related filings and have no further comments at this time. S i n c e r e l y , G u s R o d r i g u e z A c c o u n t i n g B r a n c h C h i e f